Contributors | p. vii |
Preface | p. ix |
Statins and inflammation | p. 1 |
Lipid-lowering drugs and rheology | p. 19 |
PPAR agonists in the treatment of the metabolic syndrome and Type 2 diabetes | p. 37 |
Lipid management in acute coronary syndromes | p. 59 |
Effects of statins on HDL and the implications for CHD prevention | p. 71 |
Long-term safety of lipid-lowering drugs | p. 89 |
Familial hypercholesterolaemia: current strategies and future promise | p. 101 |
Functional foods in lipid-lowering and coronary prevention | p. 119 |
Compliance with lipid-lowering drugs | p. 139 |
Lipids guidelines come of age? | p. 161 |
Index | p. 189 |
Table of Contents provided by Rittenhouse. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.